



(51) International Patent Classification:

A61K 39/395 (2006.01)

C07K 14/47 (2006.01)

A61K 33/00 (2006.01)

(21) International Application Number:

PCT/DK2022/050279

(22) International Filing Date:

14 December 2022 (14.12.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PA 2021 70621

15 December 2021 (15.12.2021) DK

(71) Applicant: Y-MABS THERAPEUTICS, INC. [US/US];

230 Park Ave, Suite 3350, New York, New York 10169 (US).

(72) Inventors: LUND-HANSEN, Torben; Ibsgård 28,

4000 Roskilde (DK). LIEBENBERG, Nico; Rådysvej 11, 3480 Fredensborg (DK). MORTENSEN, Matias Munk; Havnevej 27, 4000 Roskilde (DK). LISBY, Steen; Vibevang 2, 2970 Hørsholm (DK). PING, Li; Brunsovej 1, 3500 Værløse (DK).

(74) Agent: VALUA APS; Borgmester Jensens Alle 25C, 1. sal, 2100 Copenhagen (DK).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,

(54) Title: FORMULATIONS COMPRISING A SADA COMPLEX




Fig. 2

(57) Abstract: Disclosed are formulations comprising SADA-complex. The formulations provide for a satisfactory shelf-life without excessive disassembly or multimerization of the SADA-complex. Further disclosed is the use of the formulation for treating cancer.

SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*

Formulations comprising a SADA complex

The present specification comprises a sequence listing in computer readable format,
5 submitted together with the application. The sequence listing forms part of the disclosure and is incorporated in the specification in its entirety.

The present invention relates to compositions comprising a SADA complex, wherein said SADA complex remain stabilized on tetramer-form. Preferably the composition is a pharmaceutical composition.

10 The invention further relates to the treatment of cancer using the composition of the invention.

Technical Background

Protein drugs are typically formulated as an aqueous formulation comprising ingredients
15 that stabilizes the proteins in order to secure a satisfactory shelf-life.

The self-assembling and disassembling (SADA) technology was originally disclosed in WO 2018204873A1, and make use of SADA domains having the property of assembly and disassembly depending on concentration. Complexes comprising a SADA domain typically exists in at least two distinct forms, a tetrameric form at high concentration and a
20 monomeric form at low concentration.

SADA-complexes may be designed so that the tetrameric form has a molecular weight well above the renal clearance limit and the monomeric form has a molecular weight below the renal clearance limit, meaning that the tetrameric form will have a high plasma-half-life and the monomeric form has a low plasma half-life.

25 Since SADA-complexes are mainly administered in tetrameric form it provides a challenge to the formulation thereof, because the formulation should not only provide for a satisfactory stability of the protein, it should also secure that the SADA-complex remains on tetrameric form without excessive disassembly to monomers or agglomeration to multimers.

Summary of the invention

The present disclosure provides compositions comprising SADA domains as a part of a SADA-complex permitting effective delivery of a payload to a target site of interest, while minimizing risk of off-target interactions. For optimal delivery of a payload, it is desirable that the SADA-complex in tetramer-form is highly stable in the composition/solution. However, ensuring the stability of said compositions is a challenge. The challenge is to ensure that the composition comprises SADA-complexes predominantly in the higher-order tetramerized state, that said SADA-complexes remains on the tetramer-form and at the same time avoid multimerization, aggregation and precipitation thereof as well as product loss.

It is desirable that the SADA complex is administered on tetrameric form, because the tetrameric form having a size well above the renal clearance limit will remain in the blood circulation for a sufficient time to allow binding to the site of interest, whereas the monomeric form will be rapidly lost from the circulation because its size is below the renal clearance. In total this provides the particular desirable properties of SADA-complexes, that when administered on tetrameric form remains sufficiently long in circulation to bind to the site of interest, and complexes that do not bind a target will gradually disintegrate into monomers that will be lost via the kidneys. The present disclosure provides a composition ensuring the needed stability of the SADA-complex.

In a first aspect the invention relates to an aqueous composition comprising

- a. A SADA-complex comprising a SADA domain and at least one additional domain in an amount of 5-50 g/L;
- b. A buffer-system;
- c. One or more stabilizing agents; and
- d. One or more surfactants;

wherein the pH is in the range of 5-6, and the SADA-complex is predominantly on the tetrameric form, and the ionic strength is in the range of 5-150 mM.

It has surprisingly been realized that the formulation is capable of stabilizing the SADA-complexes upon storage and further to maintain the SADA complex predominantly on tetrameric form.

The SADA-complex preferably comprises a SADA-domain and two binding sites, one capable of binding a tumor antigen, the other binding site capable of binding a chelator complexing a metal ion. The chelator may be DOTA or a compound comprising a DOTA ring system.

In a second aspect the invention relates to the use of a composition according to the

5 invention for treating or diagnosing cancer.

In a preferred embodiment the invention relates to the use of a composition according to the invention in a method comprising the steps of:

a. Administering a composition according to the invention to a patient in need of the treatment or diagnosing; and

10 b. After a period administering a DOTA-compound binding a radionuclide.

In a third aspect the invention relates to a kit comprising the composition of the invention and preferably, instructions for use and/or DOTA binding a radionuclide.

Additional aspects are provided in the claims.

15

Detailed Disclosure

The present invention relates to Self Assembly and Dis-Assembly (SADA) technology that has been described in the international patent application with publication number WO 2018204873A1, incorporated herein by reference. The technology is based on SADA-

20 domains, small polypeptides that have the property of self assembly and disassembly depending on concentration. Examples of a SADA polypeptide is a polypeptide that comprises a tetramerization domain of p53, p63, p76, hnRNP, SNAP-23, Stefin B, KCNQ4, CBFA2T1 and any other examples of such polypeptides provided in said international patent application, without limitation.

25 According to the present specification, a SADA-complex is intended to mean a polypeptide comprising a SADA domain and at least one additional domain.

SADA-complexes will self-assemble and form multimers, in particular tetramers, at high concentration and disassemble into monomers at low concentration. This has the

consequence that a SADA-complex on tetrameric form will, when administered to a patient, be diluted in plasma and gradually disassemble into monomers. If a SADA complex is designed so the multimeric form has a size above the renal clearance limit and the monomer has a size below the renal clearance limit, the multimer will have a long plasma half life
5 whereas the monomer has a low plasma half life.

For SADA-complexes comprising a binding site, binding to a tissue antigen, SADA-complex will rapidly bind to the antigen target and be localized at the target tissue, whereas unbound SADA complex will rapidly disassemble and be cleared from the plasma by renal clearance.

Some embodiments of the present invention are provided in the claims.

10 According to an embodiment, the invention concerns an aqueous composition comprising

- a. A SADA-complex, comprising a SADA domain and at least one additional domain, in an amount of 5-50 g/L;
- b. A buffer-system;
- c. One or more stabilizing agents; and
- 15 d. One or more surfactants;

wherein the pH is in the range of 5-6, and the ionic strength is in the range of 5-150 mM.

Preferably, the SADA complex is predominantly of multimeric/tetrameric form.

The formulation of the invention has the advantage of ensuring the stability of the
20 composition. The inventors have realized that the formulation of the invention secures a high stability of the SADA complexes and is capable of maintaining the SADA-complexes in tetrameric form upon storage and further protect the protein against protein degradation. Thus, the compositions of the invention provide a solution of tetrameric SADA-complexes that remain on tetrameric form and reduces protein degradation after and during storage.
25 Thus, the formulations of the invention provide SADA-molecules with a desirable high shelf-life.

According to an embodiment, the invention concerns the composition of the invention, wherein the ionic strength is in the range of 5-150 mM, 10-135 mM, 20-120 mM or 25-100 mM.

According to an embodiment, the invention concerns the composition of the invention, comprising a SADA-complex in an amount selected among 5-50 g/L, 6.25-45 g/L, 7.5-40 g/L, 9.75-35 g/L, 10-20 g/L, and preferably 10-15 g/L.

According to an embodiment, the SADA-complex comprises two binding sites and a SADA domain, wherein the first binding site is capable of binding to a target antigen and the second binding site is capable of binding to a payload, such as a cytotoxic agent, a radionuclide or a compound capable of binding a payload.

In some embodiments the first and/or second binding site is or comprises an antibody component, such as an antigen binding fragment of an antibody, a scFv or a nanobody.

Preferably, the first and/or second binding sites is (are) a scFv.

In some embodiments the first binding site is specific for a cell surface target, such as a tumor antigen.

According to an embodiment the binding site specific for a tumor antigen is anti-GD2, anti-CD20, anti-CD38, anti-Globo H, anti-GPA33, anti-PSMA, anti-polysialic acid, anti-Lewy, anti-LiCAM, anti-HER2, anti-B7H3, anti-CD33, anti-peptide/MHC, anti-glypican3, or anti GD3 binding domain.

Accordingly, the invention concerns the composition of the invention, wherein the first binding site is capable of binding to a tumor antigen.

According to an embodiment, the invention concerns the composition according to the invention, wherein the first binding site is capable of binding to GD2, B7-H3, CD20, GPA33 or CD38.

GD2 is a disialoganglioside, which can be considered a tumor-associated antigen.

B7-H3 also known as CD276 is an immune checkpoint molecule and a costimulatory/coinhibitory immunoregulatory protein, which can be considered a tumor-associated antigen.

CD20 is a membrane-embedded surface molecule, which can be considered a tumor-associated antigen.

GPA33 is a glycoprotein and a cell surface antigen, which can be considered a tumor-associated antigen.

CD38, also known as cyclic ADP ribose hydrolase, is a glycoprotein, which can be considered a tumor-associated antigen.

According to an embodiment, the invention concerns the composition according to the invention, wherein the first binding site comprises a sequence

- 5 a. Comprising the CDR sequences of SEQ ID NO: 1-6 and
- b. Having at least 90 %, 95%, 96%, 97% 98% or preferably at least 95% sequence identity, to SEQ ID NO: 7.

According to one preferred embodiment the first binding site is capable of binding GD2 and comprises the sequence of SEQ ID NO: 7.

- 10 According to an embodiment, the invention concerns the composition according to the invention, wherein the first binding site comprises a sequence

- a. Having at least 90 %, 95%, 96%, 97% 98% or preferably at least 95% sequence identity, to SEQ ID NO: 8; and a sequence
- b. Having at least 90 %, 95%, 96%, 97% 98% or preferably at least 95% sequence
- 15 identity, to SEQ ID NO: 9.

CD38, also known as cyclic ADP ribose hydrolase, is a glycoprotein, which can be considered a tumor-associated antigen.

According to an embodiment, the invention concerns the composition according to the invention, wherein the first binding site comprises a sequence

- 20 a. Comprising the CDR sequences of SEQ ID NO: 29-34 and
- b. Having at least 90 %, 95%, 96%, 97% 98% or preferably at least 95% sequence identity, to SEQ ID NO: 35.

Preferably, the first binding site of this embodiment is capable of binding CD38.

- 25 In a preferred embodiment, the first binding site is capable of binding CD38 and comprises the sequence of SEQ ID NO: 35.

According to another embodiment, the invention concerns the composition according to the invention, wherein the first binding site comprises a sequence

- a. Having at least 90 %, 95%, 96%, 97% 98% or preferably at least 95% sequence identity, to SEQ ID NO: 36 and a sequence

- b. Having at least 90 %, 95%, 96%, 97% 98% or preferably at least 95% sequence identity, to SEQ ID NO: 37.

According to an embodiment, the invention concerns the composition according to the invention, wherein the second binding site is capable of binding to a chelator.

In principle any chelator may be used according to the invention, provided that the second binding site is capable of binding said chelator.

According to an embodiment, the invention concerns the composition according to the invention, wherein the second binding site is capable of binding to DOTA, or a compound comprising a DOTA ring system, or capable of binding DOTA or a compound comprising a DOTA ring system when DOTA is chelated to a metal ion, e.g. lutetium such as $^{175}\text{Lu}^{3+}$ or $^{177}\text{Lu}^{3+}$.

DOTA (Dodecane Tetraacetic Acid) is also referred to as 1,4,7,10-tetraazacyclododecane-1,4,7 10-tetraacetic acid, and has the formula $(\text{CH}_2\text{CH}_2\text{NCH}_2\text{CO}_2\text{H})_4$ also known as

$\text{C}_{16}\text{H}_{28}\text{N}_4\text{O}_8 \cdot x\text{H}_2\text{O}$.

A compound comprising a DOTA ring system is in this specification intended to mean a compound comprising DOTA where to additional groups or moieties are attached. Examples of such compounds include Benzyl-DOTA and the bispecific chelators disclosed in WO2019010299A, incorporated by reference.

According to an embodiment, the invention concerns the composition according to the invention, wherein the second binding site:

- a. Comprises the CDR sequences of SEQ ID NO: 23-28, and
- b. Comprising a polypeptide with at least 90 %, 95%, 96%, 97% 98% or preferably at least 95% sequence identity, to SEQ ID NO: 35.

Preferably, the second binding site of this embodiment is capable of binding DOTA-metal, i.e. DOTA chelating a metal ion such as lutetium, preferably Lu^{3+} .

According to this embodiment, the invention concerns the composition according to the invention, wherein the second binding site is capable of binding DOTA-metal and comprises a sequence

- a. with at least 90 %, 95%, 96%, 97% 98% or preferably at least 95% sequence identity, to SEQ ID NO: 10 and a sequence
- b. with at least 90 %, 95%, 96%, 97% 98% or preferably at least 95% sequence identity, to SEQ ID NO: 11.

5 According to an embodiment, the invention concerns the composition according to the invention, wherein the SADA-domain comprises a sequence disclosed in SEQ ID No. 12 - 19 or a sequence that differs from one of the sequences SEQ ID NO: 12-19 by 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 substitutions.

The p53 tetramerization domain comprising the sequence of SEQ ID NO: 12, more preferred
10 amino acids 6-36 of SEQ ID NO: 12, is a preferred SADA domain.

The SADA-complexes may according to the invention comprise additional elements, including but not limited to linkers separating different parts of the complex, antibody fragments apart from binding sites, such as constant regions and antigen fragments binding to and capable of eliciting effector or immune reactions.

15 According to an embodiment, the SADA complex comprises linkers.

Linkers also sometimes known as spacers are short amino acid sequences created to separate two domains in a single polypeptide, allowing the two domains to fold and operate without steric hindrance from an adjacent domain. Linkers are known in the art and the present invention is not limited to any particular sequence of the linkers. In general, the
20 purpose of linkers is to connect and/or separate different elements of the complex and are typically mainly composed of small hydrophilic amino acids such as glycine, serin and threonine.

According to an embodiment, the invention concerns the composition according to the invention, wherein the SADA complex comprises linkers with a sequence selected among
25 SEQ ID NO: 20 multiplied by an integer between 1-6.

Another suitable linker that may be used according to the invention is an IgG3 spacer domain, such as the IgG3 spacer domain is disclosed in SEQ ID NO: 21.

In some embodiments the SADA-complex consists of a SADA domain and 2 binding sites such as scFv's. In some embodiments the SADA-complex comprises anti-GD2 scFv -anti-DOTA scFv
30 – p53 tetramerization domain connected by linkers and/or spacers. In some embodiments

the SADA-complex has the following structure: anti-GD2 light chain Fv – anti-GD2 heavy chain Fv – anti-DOTA heavy chain Fv -anti-DOTA light chain Fv – p53 tetramerization domain connected by linkers and/or spacers.

- 5 Examples of suitable SADA complexes according to the invention includes the GD2-SADA conjugate comprising the amino acid sequence of SEQ ID NO: 22, the CD38-SADA conjugate comprising the amino acid sequence of SEQ ID NO: 38, the B7-H3-SADA conjugate comprising the amino acid sequence of SEQ ID NO: 39, the CD20-SADA conjugate comprising the amino acid sequence of SEQ ID NO: 40 and the GPA33-SADA conjugate comprising the
- 10 amino acid sequence of SEQ ID NO: 41.

According to the invention, the composition according to the invention, comprises a buffer system such as an organic acid or an alkali metal salt thereof.

Preferably, the buffer is selected among acetate, citrate, histidine, citrate-histidine, acetate-histidine and succinate.

- 15 Preferred examples include acetate buffer, comprising acetic acid and sodium acetate.

Sodium acetate is also known as Acetic acid sodium salt and has the Formula CH_3COONa .

According to an embodiment, the invention concerns the composition according to the invention, comprising a buffer in an amount selected among 5-30 mM, 10-25 mM and preferably 20 mM.

- 20 According to an embodiment, the stabilizing agent is selected among polyols, in particular sugar alcohols and non-reducing sugars.

Preferred examples include sucrose, trehalose, sorbitol, glycerol and inositol.

The stabilizer maintains or extends the time, wherein the active pharmaceutical ingredient maintains the desirable properties during storage.

- 25 According to an embodiment, the invention concerns the composition according to the invention comprising a stabilizing agent, preferably sucrose, in an amount selected among, 200-600 mM, 225-500 mM, 250-300 mM, and preferably 275 mM.

The invention also concerns a composition, wherein the surfactant is a nonionic surfactant.

Nonionic surfactants may comprise/consist of long chain polymers which do not dissociate, consisting of a hydrophilic head group and a hydrophobic tail.

According to an embodiment, the invention concerns a composition wherein the surfactant is Polyethylene glycol sorbitan monolaurate, Poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol) or Polyethylene glycol sorbitan monooleate,
5 Polyoxyethylenesorbitan monooleate.

Polyethylene glycol sorbitan monolaurate, also known as polyoxyethylenesorbitan monolaurate, is known in the art. A preferred Polyethylene glycol sorbitan monolaurate is commercially available as Polysorbate® 20 or TWEEN® 20.

10 Polyethylene glycol sorbitan monooleate, also known as polyoxyethylenesorbitan monooleate, is also known in the art. A preferred Polyethylene glycol sorbitan monooleate is commercially available as Polysorbate® 80 or TWEEN® 80.

Poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol) is also known in the art. A preferred Poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol) is commercially available as Kolliphor® P188 or Poloxamer® 188.
15

Polyethylene glycol sorbitan monolaurate is a preferred surfactant for use according to the invention.

According to an embodiment, the invention concerns compositions, comprising a surfactant in an amount selected among 0.1-0.3 g/L, 0.15-0.25 g/L, 0.16-0.24 g/L, 0.17-0.23 g/L, 0.18-
20 0.22 g/L, 0.19-0.21 g/L and preferably 0.20 g/L.

The compositions of the invention may have a pH selected among 5-6, 5.1-5.9, 5.2-5.8, 5.3-5.7, 5.4-5.6 and preferably 5.5.

The compositions according to the invention may further comprise an antioxidant.

An antioxidant can be added to a composition to protect the contents from damage caused
25 by oxidative stress. This can be advantageous for proteins comprising amino acids susceptible to oxidation particularly for proteins comprising amino acids susceptible of oxidation which amino acids are exposed on the surface of the proteins. Example of amino acids susceptible to oxidation includes residues such as methionine and (free) cysteine.

A preferred antioxidant for use according to the invention is Methionine.

According to an embodiment, the invention concerns compositions, comprising an antioxidant, such as methionine, in an amount selected among, 5-15 mM, 6-14 mM, 7-13 mM, 8-12 mM, 9-11 mM and preferably 10 mM.

The invention further concerns a composition according to the invention, that does not
5 comprise salt, or only comprise salt in a low concentration e.g. below 50 mM.

The inventors have realized that salts in general destabilizes SADA complexes, and it is therefore preferred to limit the amounts of salts such as NaCl, KCl, or similar salts; in the composition.

A preferred composition according to the invention, comprises

- 10
- a. SADA-complex in an amount of 15 g/L
 - b. Sodium acetate in an amount of 20 mM
 - c. Sucrose in an amount of 275 mM
 - d. Polysorbate 20 in an amount of 0.2 g/L

wherein the pH is 5,5 and the SADA complex is predominantly on tetrameric form.

15 Optionally, the composition further comprises 10 mM methionine.

The term predominantly on tetramer-form is in the present specification and claims intended to mean that the majority of the SADA-complexes are on tetramer-form, e.g., at least 50% w/w; at least 60% w/w; at least 70% w/w; at least 80% w/w; at least 90% w/w; or at least 95% w/w.

20 According to an embodiment, the composition according to the invention is a pharmaceutical composition.

The SADA-complexes of the invention may be prepared using methods known in the art.

In a preferred embodiment, a nucleic acid encoding the desired amino acid sequence of the complex is provided. A construct comprising the nucleic acid sequence provided with the
25 necessary regulatory elements to direct expression in a selected host organism, such as promoter, signal sequence ribosome recognition sites Kozak sequence, enhancers, terminator, poly adenylation sites etc. is prepared and inserted into the selected host organism that is grown under conditions leading the expression of the SADA-complex.

Finally, the SADA- complex is recovered from the growth broth using well known separation and recovery techniques.

The formulation of the invention may be prepared by dissolving the SADA-complex and other ingredients in sterile water using method known in the art.

- 5 The invention further concerns use of a composition according to the invention for treating or diagnosing cancer.

According to an embodiment, the composition according to the invention may be used for treating or diagnosing cancer expressing the tumor antigen recognized by the SADA conjugate, such as GD2, CD38, B7-H3, CD20 or GPA33.

- 10 The cancer may be selected among neuroblastoma, melanoma, sarcoma, brain tumor or carcinoma.

According to an embodiment, the invention concerns use of a composition according to the invention, wherein said cancer is selected among osteosarcoma, liposarcoma, fibrosarcoma, malignant fibrous histiocytoma, leiomyosarcoma, spindle cell sarcoma, brain tumor, small
15 cell lung cancer, retinoblastoma, HTLV-1 infected T cell leukemia and other tumors that are positive for GD2, CD38, B7-H3, CD20 or GPA33.

According to an embodiment, the invention concerns use of a composition according to any of the preceding claims, in a method comprising the steps:

- 20 a. Administering a composition according to the invention to a patient in need of the treatment or diagnosing; and
 b. After a period administering a DOTA-compound comprising a radionuclide.

The period in step b. is typically selected between 48 hours to 72 hours, such as 50 hours to 65 hours, or 55 hours to 60 hours. Preferably, the period is selected to allow the majority of unbound SADA-complex to disassemble and be cleared from the blood stream.

- 25 The method of the invention may further comprise administering a clearing agent after step a. and before step b.

According to an embodiment, the invention concerns use of a composition according to the invention, wherein the radionuclide is selected among an alpha, beta and positron emitting

radionuclide.

According to an embodiment, the invention concerns use according to the invention,

wherein the radionuclide is selected from the group consisting of ^{211}At , ^{51}Cr , ^{57}Co , ^{58}Co , ^{67}Cu , ^{152}Eu , ^{67}Ga , ^{111}In , ^{59}Fe , ^{212}Pb , ^{177}Lu , ^{223}Ra , ^{224}Ra , ^{186}Re , ^{188}Re , ^{75}Se , $^{99\text{m}}\text{Tc}$, ^{227}Th , ^{89}Zr , ^{90}Y , $^{94\text{m}}\text{Tc}$, ^{64}Cu , ^{68}Ga , ^{66}Ga , ^{86}Y , ^{82}Rb , $^{110\text{m}}\text{In}$, ^{209}Bi , ^{211}Bi , ^{212}Bi , ^{213}Bi , ^{210}Po , ^{211}Po , ^{212}Po , ^{214}Po , ^{215}Po , ^{216}Po , ^{218}Po , ^{211}At , ^{215}At , ^{217}At , ^{218}At , ^{221}Fr , ^{223}Ra , ^{224}Ra , ^{226}Ra , ^{225}Ac , ^{227}Ac , ^{227}Th , ^{228}Th , ^{229}Th , ^{230}Th , ^{232}Th , ^{231}Pa , ^{233}U , ^{234}U , ^{235}U , ^{236}U , ^{238}U , ^{237}Np , ^{238}Pu , ^{239}Pu , ^{240}Pu , ^{244}Pu , ^{241}Am , ^{244}Cm , ^{245}Cm , ^{248}Cm , ^{249}Cf , and ^{252}Cf .

Preferred examples of radionuclides for use according to the invention includes ^{177}Lu , $^{99\text{m}}\text{Tc}$,

^{64}Cu , ^{90}Y and ^{89}Zr .

According to an embodiment, the invention concerns kit comprising the composition of the invention, and a DOTA compound.

Typically, the kit further comprises instructions to use, or at least information to the user regarding where to find such information.

According to an embodiment, the invention concerns kit according to the invention, further comprising a radionuclide.

Definitions

Antibody fragment: An antibody fragment is a portion of an antibody such as F(ab')_2 , F(ab)_2 ,

Fab' , Fab , Fv , sFv and the like. Regardless of structure, an antibody fragment binds with the same antigen that is recognized by the intact antibody. For example, an 3F8 monoclonal antibody fragment binds with an epitope recognized by 3F8. The term "antibody fragment" also includes any synthetic or genetically engineered protein that acts like an antibody by binding to a specific antigen to form a complex. For example, antibody fragments include isolated fragments consisting of the variable regions, such as the "Fv" fragments consisting of the variable regions of the heavy and light chains, recombinant single chain polypeptide molecules in which light and heavy variable regions are connected by a peptide linker ("scFv proteins"), and minimal recognition units consisting of the amino acid residues that mimic the hypervariable region.

DOTA: DOTA (Dodecane Tetraacetic Acid) is also referred to as 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid, and has the formula $(\text{CH}_2\text{CH}_2\text{NCH}_2\text{CO}_2\text{H})_4$ also known as $\text{C}_{16}\text{H}_{28}\text{N}_4\text{O}_8 \cdot x\text{H}_2\text{O}$.

DOTA metal chelate: means DOTA with a complex bound metal ion.

- 5 **Derivative of DOTA:** is intended to mean a compound comprising the DOTA ring system and is capable of chelating metal ions. Examples of such compounds include Benzyl-DOTA and the bispecific chelators disclosed in WO2019010299A. Additional DOTA derivatives are disclosed in WO2010099536 A1.

- Radioactive isotope:** Examples of radioactive isotopes that can be conjugated to antibodies
 10 for use diagnostically or therapeutically include, but are not limited to, ^{211}At , ^{14}C , ^{51}Cr , ^{57}Co , ^{58}Co , ^{67}Cu , ^{152}Eu , ^{67}Ga , ^3H , ^{111}In , ^{59}Fe , ^{177}Lu , ^{32}P , ^{223}Ra , ^{224}Ra , ^{186}Re , ^{188}Re , ^{75}Se , ^{35}S , $^{99\text{m}}\text{Tc}$, ^{227}Th , ^{89}Zr , ^{90}Y , ^{123}I , ^{124}I , ^{125}I , ^{131}I , $^{94\text{m}}\text{Tc}$, ^{64}Cu , ^{68}Ga , ^{66}Ga , ^{76}Br , ^{86}Y , ^{82}Rb , $^{110\text{m}}\text{In}$, ^{13}N , ^{11}C , ^{18}F and alpha-emitting particles. Non-limiting examples of alpha-emitting particles include ^{209}Bi , ^{211}Bi , ^{212}Bi , ^{213}Bi , ^{212}Pb , ^{210}Po , ^{211}Po , ^{212}Po , ^{214}Po , ^{215}Po , ^{216}Po , ^{218}Po , ^{211}At , ^{215}At , ^{217}At , ^{218}At , ^{218}Rn , ^{219}Rn ,
 15 ^{220}Rn , ^{222}Rn , ^{226}Rn , ^{221}Fr , ^{223}Ra , ^{224}Ra , ^{226}Ra , ^{225}Ac , ^{227}Ac , ^{227}Th , ^{228}Th , ^{229}Th , ^{230}Th , ^{232}Th , ^{231}Pa , ^{233}U , ^{234}U , ^{235}U , ^{236}U , ^{238}U , ^{237}Np , ^{238}Pu , ^{239}Pu , ^{240}Pu , ^{244}Pu , ^{241}Am , ^{244}Cm , ^{245}Cm , ^{248}Cm , ^{249}Cf , and ^{252}Cf .

- Treatment:** As used herein, the terms "treatment", "treat", "treated" or "treating" refer to prophylaxis and/or therapy, particularly wherein the object is to prevent or slow down
 20 (lessen) an undesired physiological change or disorder, such as the progression of multiple sclerosis. Beneficial or desired clinical results include, but are not limited to, alleviation of symptoms, diminishment of extent of disease, stabilized (i.e., not worsening) state of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total), whether detectable or undetectable.
 25 "Treatment" can also mean prolonging survival as compared to expected survival if not receiving treatment. Those in need of treatment include those already with the condition or disorder as well as those prone to have the condition or disorder or those in which the condition or disorder is to be prevented.

- Pharmaceutical composition:** As used herein the term "Pharmaceutical composition" is
 30 intended to mean a composition for administration as a drug or medicine to a patient in need thereof. Pharmaceutical compositions are prepared from pharmaceutical grade

ingredients e.g., as described in European Pharmacopoeia 10th Edition, using methods and technologies known in the pharmaceutical or apothecary area.

Sequence identity: The term Sequence identity is intended to mean a measurement of the relatedness of two nucleic or amino acid sequences. Sequence identity is determined by

aligning the two sequences and finding the longest overlap, counting the number of matches in the overlap and calculating the sequence identity by dividing the number of matches by the number of, nucleotide or amino acid, residues in the overlap. Sequence identity is typically expressed in percent (%).

A variety of computational algorithms are available for the skilled person, for generating

sequence alignment and calculating Sequence identity. As used herein, Sequence alignment refers to Pairwise alignments. Several algorithms perform this including the sequence alignment program Clustal Omega[doi:10.1038/msb.2011.75].

As used herein the sequence alignment are performed using the algorithm:

Algorithm: Clustal Omega (1.2.4),

(<http://www.clustal.org/omega/>).

Figures

Fig. 1 shows the results of two mass photometry measurements of GD2-SADA construct at a concentration of 100 nM and 5 nM. For further details see example 1.

Fig. 2 shows the distribution of monomer, dimer and tetramer of a GD2-SADA construct dependent of the concentration. For further details see example 1.

Fig. 3 shows the design of part A, phase I trial for GD2-SADA. For further details see example

10.

Fig. 4 shows the effect of tetramerization on the tumor killing effect for a GD2-SADA conjugate. For further details see example 9.

Fig.5 shows SPECT images of tumor implanted IMR-32 athymic nude mice that had been given GD2-SADA (>90% tetramer, 10 mg/kg, IV) (top panel), GD2-monomer (2.4 mg/kg, IV)

(middle panel) and a GD2-monomer (9.6 mg/kg)(lower panel); followed by administration of ^{177}Lu -DOTA. In each panel, the first mouse was scanned 2 hours after administration of ^{177}Lu -DOTA, the following mice were scanned 24, 48 and 120 hours after administration of ^{177}Lu -DOTA, respectively. For further details see example 9.

5

Sequences

SEQ ID NO: 1-6: CDR sequences of the GD2 binding antibody 3F8 equal to the CDR sequences of the GD2-scFv;

SEQ ID NO: 7: anti-GD2 scFv;

10 SEQ ID NO 8: anti-GD2 VL

SEQ ID NO 9: anti-GD2 VH

SEQ ID NO: 10: huC825 VL;

SEQ ID NO: 11: huC825 VH

SEQ ID NO: 12-19: SADA domains disclosed in WO 2018204873A1;

15 SEQ ID NO: 20: Linker sequence;

SEQ ID NO: 21: IgG3 spacer sequence;

SEQ ID NO: 22: GD2-SADA complex.

SEQ ID NO: 23-28 CDR sequences of C825

SEQ ID NO: 29-34: CDR sequences of a CD38 binding antibody

20 SEQ ID NO: 35: anti-CD38 scFV

SEQ ID NO: 36: anti-CD38 VL

SEQ ID NO: 37: anti-CD38 VH

SEQ ID NO: 38: CD38-SADA complex

SEQ ID NO: 39: B7-H3-SADA complex

25 SEQ ID NO: 40: CD20-SADA complex

SEQ ID NO: 41: GPA33-SADA complex.

All cited references are incorporated by reference.

The accompanying Figures and Examples are provided to explain rather than limit the present invention. It will be clear to the person skilled in the art that aspects, embodiments,
5 claims and any items of the present invention may be combined.

Unless otherwise mentioned, all percentages are in weight/weight. Unless otherwise mentioned, all measurements are conducted under standard conditions (ambient temperature and pressure). Unless otherwise mentioned, test conditions are according to European Pharmacopoeia 10.0.

10

Methods and materials

GD2-SADA complex: the complex comprises an anti-GD2 scFv domain, a humanized C825 domain and a P53 SADA domain. The complex is disclosed in WO 2018/204873A1 as SEQ ID NO:31, and as SEQ ID NO: 22 in the present patent application.

15 CD38-SADA complex: the complex comprises an anti-CD38 scFv domain, a humanized C825 domain and a P53 SADA domain. The complex is disclosed in (unpublished Danish Patent application) DK PA 2021 70621 as SEQ ID NO:41, and as SEQ ID NO: 38 in the present patent application.

B7-H3-SADA complex: the complex comprises an anti-B7-H3 scFv domain, a humanized C825
20 domain and a P53 SADA domain. The complex has the amino acid sequence shown in SEQ ID NO: 39.

CD20-SADA complex: the complex comprises an anti-CD20 scFv domain, a humanized C825 domain and a P53 SADA domain. The complex is disclosed in (unpublished Danish Patent application) DK PA 2021 70621 as SEQ ID NO:42, and as SEQ ID NO: 40 in the present patent
25 application.

GPA33-SADA complex: the complex comprises an anti-GPA33 scFv domain, a humanized C825 domain and a P53 SADA domain. The complex is disclosed in (unpublished Danish Patent application) DK PA 2021 70621 as SEQ ID NO:61, and as SEQ ID NO: 41 in the present patent application.

Surfactants

- Polysorbate 20: TWEEN 20®, Polyethylene glycol sorbitan monolaurate, Polyoxyethylenesorbitan monolaurate.
- 5 • Polysorbate 80: TWEEN 80®, Polyethylene glycol sorbitan monooleate, Polyoxyethylenesorbitan monooleate. Poloxamer 188: Poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol)
- Kollifor: Poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol)

10 Examples

Example 1. Impact of SADA concentration on relative numbers of oligomeric forms measured for GD2-SADA.

For this example, a Refeyn Mass photometer (Refeyn Ltd, Oxford UK) was used according to the manufacturer's instructions, with the following settings:

- | | | |
|----|--|--|
| 15 | • Measurement principle | Label-free/ interferometric light scattering |
| | • Mass range | 4 kDa – 5 MDa |
| | • Measurement precision | +/- 2% |
| | • Single measurement mass error +/- 5% | |
| | • Resolution (FWHM) | 25 kDa@66kDa, 88kDa@660kDa |
| 20 | • Concentration range | 100 pM-100 nM (particle concentration) |
| | • Sensitivity | < 1ng of protein |
| | • Sample volume | 5-20µl |
| | • Frame rate /standard setting) | 1 kHz (raw), 100 Hz (integrated) |
| | • Field of view | 3 x 10 µm (@ 1 kHz) up to 10 x 10 µm (@300 Hz) |
| 25 | • Wavelength | 525 nm |
| | • Pixel size | 21 nm |

The GD2-SADA construct was diluted in PBS, and incubated for 60 minutes at 37°C before measuring the size distribution. Following dilutions were made: 150 nM, 100 nM, 50 nM, 10 nM, 5 nM, 1 nM and 100 pM and subjected to Mass photometry using the Refeyn Mass
30 photometer.

Exemplary spectrograms are shown in Figure 1, on top for 100 nM and below for 5 nM. In the spectrograms three peaks representing monomer, dimer and tetramer GD2-SADA can be seen and for the 100 nM concentration further a broad peak at around 500 kDa can be seen representing higher multimers of GD2-SADA. It can further be seen that at high

- 5 concentration (100 nM) a high proportion of the GD2-SADA constructs are present at tetrameric form, whereas at low concentration the majority is present a monomeric form.

Figure 2 shows the distribution of GD2-SADA construct dependent on concentration.

Example 2. Effect of Buffers and pH

- 10 GD2-SADA was prepared in 20 mM buffers at the pH indicated in the table below. The stability of the construct was determined by nanoDSF, where the T_m indicated the temperature where 50% of the protein is unfolding, meaning that a higher temperature is indicative for a higher stability. The measurements were made in quadruples. Following result were obtained:

15 Table 1. GD2-SADA; Effect of buffer and pH

Buffer	pH	T _m (°C)	
		Mean	SD
Acetate	4.5	60.5	0.9
	5.0	60.7	0.2
	5.5	61.7	1.3
Citrate	4.5	58.4	0.3
	5.0	60.7	1.2
	5.5	60.4	0.2
Histidine	5.5	60.8	0.9
	6.0	62.3	0.4
	6.5	62.3	0.5
Citrate-histidine	5.5	61.9	0.3
	6.0	61.5	0.2
	6.5	61.7	0.2
Acetate-histidine	5.5	61.9	0.3
	6.0	61.5	0.2
	6.5	61.7	0.2
Succinate	4.5	59.7	0.6
	5.0	60.9	0.3
	5.5	61.2	0.4

The results showed that acetate and histidine provided a higher stability than citrate and succinate buffers. A pH value >5.5 was found to provide best stability.

Example 3. Effect of salt and sucrose

- 5 GD2-SADA was prepared in 20 mM buffers at pH 5.5 and salt (sodium chloride) or sucrose added as indicated. The stability of the construct was determined by nanoDSF, where the T_m indicated the temperature where 50% of the protein is unfolding, meaning that a higher temperature is indicative for a higher stability. The measurements were made in quadruples. Following result were obtained:

10

Table 2: GD2-SADA: nanoDSF results: effect of salt and sucrose

Buffer (20 mM, pH 5.5)	NaCl (mM)	Sucrose (mM)	T_m (°C)	
			Mean	SD
Acetate	150	0	60.9	0.2
Citrate	150	0	60.4	0.5
Histidine	150	0	60.7	0.7
Citrate-histidine	150	0	60.7	0.6
Acetate-histidine	150	0	60.6	0.7
Succinate	150	0	60.8	0.2
Acetate	0	275	62.7	0.5
Citrate	0	275	61.4	0.3
Histidine	0	275	62.7	0.3
Citrate-histidine	0	275	61.1	0.0
Acetate-histidine	0	275	63.8	0.3
Succinate	0	275	62.5	0.4

The results showed that sucrose is stabilizing the construct whereas salt (sodium chloride) is destabilizing.

15

Example 4. Effect of surfactants in an accelerated aging study

Exemplary formulations were prepared, each comprising 20 mM acetate buffer and 275 mM sucrose and further comprising:

Table 3 GD2-SADA: Formulations for accelerated aging study

#	pH	Surfactant	GD2-SADA concentration (mg/ml)
1	5.5	0.2 g/l Polysorbate 20	15
2	5.5	3.0 g/l Polysorbate 20	15
3	5.5	0.2 g/l Polysorbate 80	15
4	5.5	3.0 g/l Polysorbate 80	15
5	5.0	0.2 g/l Poloxamer 188	15
6	5.5	0.2 g/l Poloxamer 188	15
7	6.0	0.2 g/l Poloxamer 188	15
8	5.5	3.0 g/l Poloxamer 188	15
9	5.5	0.2 g/l Poloxamer 188	10
10	5.5	3.0 g/l Poloxamer 188	10
11	5.5	0	15
12	5.5	0	10

5

The solutions were stored for one or two weeks at 40°C and were thereafter analyzed for purity by size exclusion HPLC, and the purity drop for the main peak and the main recovery based on the recovery before incubation were calculated. The results are shown in the tables 4 and 5 below.

10

Table 4. GD2-SADA: Accelerated storage data measured by SE-HPLC after 1 week @ 40°C

#	Conc. (mg/ml)	pH	Polysorbate 20 (g/l)	Polysorbate 80 (g/l)	Poloxamer 188 (g/l)	Purity drop	Mean recovery (%)
1	15	5.5	0.2	0	0	3.4	96.5
2	15	5.5	3.0	0	0	3.4	92.5
3	15	5.5	0	0.2	0	3.5	96.0
4	15	5.5	0	3.0	0	3.5	97.3
5	15	5.0	0	0	0.2	4.3	85.3

6	15	5.5	0	0	0.2	3.5	81.7
7	15	6.0	0	0	0.2	3.1	82.5
8	15	5.5	0	0	3.0	3.3	90.9
9	10	5.5	0	0	0.2	1.8	86.2
10	10	5.5	0	0	3.0	2.0	95.6
11	15	5.5	0	0	0	3.8	77.7
12	10	5.5	0	0	0	2.4	82.2

Table 5. GD2-SADA: Accelerated storage data measured by SE-HPLC after 2 weeks @ 40°C

#	Conc. (mg/ml)	pH	Polysorbate 20 (g/l)	Polysorbate 80 (g/l)	Poloxamer 188 (g/l)	Purity drop	Mean recovery (%)
1	15	5.5	0.2	0	0	4.9	98.6
2	15	5.5	3.0	0	0	4.9	92.2
3	15	5.5	0	0.2	0	5.3	97.3
4	15	5.5	0	3.0	0	5.2	97.5
5	15	5.0	0	0	0.2	7.6	83.4
6	15	5.5	0	0	0.2	5.4	86.1
7	15	6.0	0	0	0.2	5.6	79.2
8	15	5.5	0	0	3.0	5.4	87.2
9	10	5.5	0	0	0.2	2.4	81.1
10	10	5.5	0	0	3.0	2.6	96.5
11	15	5.5	0	0	0	5.2	73.8
12	10	5.5	0	0	0	3.0	77.4

The results showed that surfactants improved mean recovery. In this example a better
 5 recovery was obtained using Polysorbate 20/80 or high concentration of Poloxamer 188.

Example 5: GD2-SADA formulation

An exemplary formulation of GD2-SADA was made taking advantage of the conclusions in
 examples 1-4. Further methionine was added as an antioxidant to protect M199 and
 10 Polysorbate from oxidation.

Table 6. GD2-SADA formulation

Component	Amount	Function
GD2-SADA	15g/l	API
Sodium Acetate	20 mM	Buffer
Sucrose	275 mM	Stabilizing agent
Polysorbate 20	0.2 g/l	Surfactant
Methionine	10 mM	Antioxidant
pH	5.5	

Example 6: Compatibility of GD2-SADA formulation

To demonstrate the compatibility of the formulation during clinic administration, an in use stability study was performed to demonstrate suitable product recovery and stability for the GD2-SADA formulation according to example 6 for 4 hours at room temperature including administration time.

The study covered a concentration range from 0.05 mg/mL to 10 mg/mL. Dilution of GD2-SADA was done in normal saline (NaCl 0.9%). The 50 mL IV-bag containing GD2-SADA dilutions were connected to an infusion set and infusion filter. Samples were taken by allowing GD2-SADA dilutions to pass from the 50mL IV-bag through the infusion set and filter.

Purity, potency, physicochemical, and particle results were all within the expected range and comparable between T = 0 hours and T = 4 hours.

Table 7: Stability study results for GD2-SADA formulation:

Analytical method	0.05 mg/mL		10 mg/mL	
	T = 0 hours	T = 4 hours	T = 0 hours	T = 4 hours
Visible Particles	Essentially free of visible particles and bubbles	Essentially free of visible particles and bubbles	Essentially free of visible particles and bubbles	Essentially free of visible particles and bubbles
Subvisible Particles $\geq 25 \mu\text{m}$	5 Particles/mL	3 Particles/mL	4 Particles/mL	4 Particles/mL
Subvisible Particles $\geq 10 \mu\text{m}$	29 Particles/mL	29 Particles/mL	52 Particles/mL	22 Particles/mL

Relative potency (by GD2 SPR)	Comparable to reference standard with (relative) potency between 50 to 150 % ^b	Comparable to reference standard with (relative) potency between 50 to 150 %	Comparable to reference standard with (relative) potency between 50 to 150 %	Comparable to reference standard with (relative) potency between 50 to 150 %
A280 (content protein)	0.06 mg/mL	0.056 mg/mL	9.89 mg/mL	9.89 mg/mL
	113 % Recovery	106% Recovery	99% Recovery	99% Recovery
Non-reduced SDS cGE Dimer	20.3%	20.3%	20.7%	20.7%
Non-reduced SDS cGE Monomer	72.5%	72.5%	71.9%	71.9%
Non-reduced SDS cGE Monomer + Dimer	92.8%	92.7%	92.6%	92.6%
Relative potency (by GD2 SPR)	106% ^b	87%	101%	101%
Relative potency (by DOTA SPR)	95%	102%	104%	106%
Non-reduced SDS-cGE HMWS	6.4%	6.5%	6.7	6.7%
Non-reduced SDS-cGE LMWS	0.8%	0.8%	0.7	0.7%
Reduced SDS-cGE HMWS	1.5%	1.4%	1.4%	1.5%
Reduced SDS-cGE LMWS	3.3%	3.2%	3.4%	3.4%
Reduced SDS-cGE Purity	95.2%	95.4%	95.1%	95.1%
SE-HPLC HMWS	4.4%	4.9%	4.9%	5.3%
SE-HPLC LMWS 1	0.7%	0.6%	0.7%	0.7%
SE-HPLC Tetramer	94.5%	94.0%	93.9%	93.5%
SE-HPLC other LMWS	0.5%	0.6%	0.5%	0.5%

Osmolality	288 mOsm/kg	288 mOsm/kg	337 mOsm/kg	338 mOsm/kg
pH	5.5	5.8	5.5	5.5

Protein recovery was 99 and 106 % for the tested concentrations. The recovery was calculated as the percentage difference between the observed concentrations and expected theoretical concentration.

To assess the potential effect of surface adherence to the infusion materials at worst-case conditions, the lowest dose concentration (0.05 mg/mL) was prepared using precision pipettes to minimize variation from the preparation procedure, which would not normally affect the dose administered in the clinic where the entire volume was infused. This experiment identified a protein recovery of 106%, indicating that GD2-SADA surface adherence to the administration materials was negligible.

In conclusion, the formulation used was evaluated to be stable within the tested concentration range of 0.05 mg/mL to 10 mg/mL, as well as during storage and handling of the GD2-SADA for up to 4 hours at room temperature.

Example 7: Stability to support shelf life

The stability results of the supportive shelf life study are summarized in Table 8 for the long-term stability study ($5 \pm 3^\circ\text{C}$) and in Table 9 for accelerated conditions ($25 \pm 2^\circ\text{C}$).

The long-term stability study shows that GD2-SADA is stable in tetramer form (>94%) at 2–8°C for at least 9 months in formulations containing 20 mM sodium acetate buffer, 275 mM sucrose and 0.2 g/L polysorbate 20 at pH of 5.5. In addition, the accelerated stability data shows that GD2-SADA is stable in tetramer form (>94%) at 25 °C for at least 3 months.

In addition, the stability data shows that GD2-SADA is stable in current formulation regarding potency, purity and impurity.

Table 8 Long-term stability data for the GD2-SADA formulation (stored at $5 \pm 3^\circ\text{C}$)

Test method	Unit	0 months (M)	3M	6M	9M
Degree of opalescence, clarity	N/A	Slightly opalescent	Slightly opalescent	Slightly opalescent	Slightly opalescent
Clarity	NTU	5	6	6	6
	N/A	< reference suspension II	= reference suspension II	= reference suspension II	= reference suspension II
Degree of colouration of liquids	BY-scale	<BY6	<BY6	<BY6	<BY6
Visible particles	N/A	Essentially free of visible particles	Not tested	Essentially free of visible particles	Not tested
A280 (content protein)	mg/mL	14.5	14.7	14.7	14.7
Non-reduced SDS-cGE	% monomer	71.4	72.6	71.9	71.4
	% dimer	20.8	20.2	20.7	20.9
	% Monomer + % dimer	92.3	92.8	92.6	92.4
Relative potency SPR (DOTA)	%	99	106	106	111
Relative potency SPR (GD2)	%	112	108	99	99
Reduced SDS-cGE	% purity	94.9	95.8	95.0	94.7
	% LMW species	3.9	3.1	3.7	4.3
	% HMW species	1.2	1.1	1.2	1.1
Non-reduced SDS-cGE	% HMW species	6.9	6.5	6.7	6.8
	% LMW species	0.9	0.7	0.7	0.8
SE-HPLC	% Tetramer	94.7	94.4	95.4	94.5

Test method	Unit	0 months (M)	3M	6M	9M
	% HMW species	4.1	4.4	3.2	4.2
	% LMW species 1	0.6	0.7	0.8	0.7
	% other LMWs	0.6	0.5	0.6	0.6
Bioburden	cfu/ 10 mL	0	Not tested	Not tested	Not tested
Osmolality	mOsmol/kg	362	Not tested	367	Not tested
pH	N/A	5.5	5.5	5.5	5.5

Table 9 Accelerated stability data for the GD2-SADA formulation (stored at 25 ± 2°C)

Test method	Unit	0 months (M)	1M	2M	3M
Degree of opalescence, clarity	N/A	Reference suspension II	Reference suspension II	Reference suspension II	Reference suspension II
Clarity	NTU	6	6	6	6
	N/A	slightly opalescent	slightly opalescent	slightly opalescent	slightly opalescent
Degree of colouration of liquids	BY-scale	< BY6	< BY5	< BY6	< BY6
Container and closure	N/A	no dye ingress	Not tested	Not tested	Not tested
Visible particles	N/A	Essentially free of visible particles	Not tested	Essentially free of visible particles	Essentially free of visible particles
Subvisible particles (SvP)	N/A	≥ 2 µm: 3494 ≥ 5 µm: 413 ≥ 10 µm: Pass ≥ 25 µm: Pass	Not tested	Not tested	≥ 2 µm: 3737 ≥ 5 µm: 393 ≥ 10 µm: Pass ≥ 25 µm: Pass
A280 (content protein)	mg/mL	14.8	14.8	14.8	14.8

Test method	Unit	0 months (M)	1M	2M	3M
Non-reduced SDS-cGE	% monomer	72.9	72.2	71.6	71.4
	% dimer	20.2	20.6	20.3	20.2
	% Monomer + % dimer	93.1	92.8	91.9	91.6
Relative potency SPR (DOTA)	%	102	105	103	112
Relative potency SPR (GD2)	%	100	97	96	94
Reduced SDS-cGE	% purity	96.5	95.0	91.2	90.0
	% LMW species	2.5	3.9	6.3	8.1
	% HMW species	1.0	1.1	2.5	1.9
Non-reduced SDS-cGE	% HMW species	6.2	6.5	6.1	6.0
	% LMW species	0.7	0.7	0.8	0.9
SE-HPLC	% Tetramer	95.1	95.6	94.7	94.4
	% HMW species	4.1	3.0	3.6	3.8
	% LMW species 1	0.5	0.9	1.2	1.3
	% other LMWs	0.3	0.5	0.5	0.5
Osmolality	mOsmol/kg	368	Not tested	Not tested	Not tested
pH	N/A	5.5	5.5	5.5	5.5

Example 8. Thermal stability of additional SADA-conjugates

Sample solution were centrifuged for 1 h at 20,000 X g, 4°C in a tabletop centrifuge. The supernatant was buffer exchanged into stock buffer (Histidine and Acetate with and without

150 mM NaCl) and samples were further diluted to 10 μ M. Sucrose was spiked in for all conditions with target sucrose concentration. Each sample was measured as duplicates by nanoDSF (Ratio 350/330 nm for protein unfolding T_m). There are five molecules included in this study. These molecules have the same DOTA binding and P53 sequence, but with different antigen binding sites, such as GD2, CD38, B7H3, CD20 and GPA33.

As shown in table 10 and 11, 150mM NaCl has a negative impact on thermal stability of all investigated SADA molecules, as indicated by a decreased T_m value, compared with buffer groups (pH5.5 acetate and pH6.0 histidine). In addition, 275 mM sucrose has a positive impact on thermal stability of all investigated SADA molecules, as indicated by an increased T_m value, compared with buffer groups (pH5.5 acetate and pH6.0 histidine). This salt destabilizing and sugar stabilizing effect is universal on all investigated SADA molecules, even though the antigen binding sites are different. Therefore, we conclude the salt destabilizing and sugar stabilizing effect is mainly driven by DOTA binding and P53 part.

Table 10 Thermal stability (T_m) overview of tested SADA molecules in pH 5.5 acetate buffer W/O salt and sugar

	Acetate buffer (pH 5.5)	Acetate + 150 mM NaCl (pH 5.5)	Acetate + 275 mM Sucrose (pH 5.5)
CD38-SADA(T_m , °C)	60.41	59.92	61.27
B7H3-SADA(T_m , °C)	53.78	52.86	55.05
CD20-SADA (T_{m1} , °C)	55.85	54.67	57.2
CD20-SADA (T_{m2} , °C)	71.2	68.55	72.37
GD2-SADA(T_m , °C)	60.74	60.42	61.91
GPA33-SADA (T_{m1} , °C)	59.87	60.62	61.02
GPA33-SADA (T_{m2} , °C)	70.10	65.43	71.35

Table 11 Thermal stability (T_m) overview of tested SADA molecules in pH 6.0 histidine buffer W/O salt and sugar

	Histidine buffer (pH 6.0)	Histidine + 150 mM NaCl (pH 6.0)	Histidine + 275 mM Sucrose (pH 6.0)
CD38-SADA(T_m , °C)	60.68	60.09	61.10
B7H3-SADA(T_m , °C)	53.93	53.69	55.07
CD20-SADA (T_{m1} , °C)	56.05	54.9	57.3
CD20-SADA (T_{m2} , °C)	71.7	68.56	72.35

GD2-SADA(T _m , °C)	60.8	60.5	62.04
GPA33-SADA (T _{m1} , °C)	59.93	60.19	61.21
GPA33-SADA (T _{m2} , °C)	70.26	65.71	71.53

Example 9. GD2-SADA tetramer has better PK profile and thus better tumor uptake as well as the tumor killing effect.

To better evaluate tetrameric role, we compared GD2-SADA drug candidate to an obligate monomeric version, termed (P53^{-/-})GD2-SADA, where the entire SADA domain was eliminated, resulting in a final protein size of approximately 54 kDa.

GD2-SADA and (P53^{-/-})GD2-SADA were compared regarding plasma pharmacokinetics and anti-tumor efficacy. In summary, the result demonstrates GD2-SADA tetramer, altering the plasma exposure profile (Table 12), and improving the therapeutic efficacy of GD2-SADA (Fig.4), compared to GD2-SADA, (P53^{-/-})GD2-SADA in monomer form. This was also supported by SPECT/CT imaging (Fig.5) which demonstrated substantially higher tumor binding and persistence for GD2-SADA compared to (P53^{-/-})GD2-SADA monomer. Therefore, it is important to keep GD2-SADA in tetramer form by current claimed composition.

Table 12. (P53^{-/-})GD2-SADA pharmacokinetic data summary (n=6)

Study groups	Dose level (per mouse)	Half-life (hr)	T _{max}	C _{max} (%ID/g)	AUC _{0.5-72} (h × %ID/g)
(P53 ^{-/-})GD2-SADA (high dose)	9.6 mg/kg (240 µg)	7.8	0.5 h	17.2±3.4	125.5±3.7
(P53 ^{-/-})GD2-SADA (low dose)	2.4 mg/kg (60 µg)	6.9	0.5 h	18.5±1.4	138.8±2.6
GD2-SADA (reference dose)	10 mg/kg (250 µg)	8.8	0.5 h	45.6±19.0	330.3±21.5
GD2-SADA (low dose)	2.5 mg/kg (62.5 µg)	5.8	0.5 h	41.4±0.6	362.6±6.4

Example 10. Phase I trial of GD2-SADA:¹⁷⁷Lu-DOTA Drug Complex in Patients with recurrent or refractory metastatic solid tumors known to express GD2, including Small Cell Lung Cancer, Sarcoma and Malignant Melanoma.

The trial will be divided in 3 separate parts:

- A. GD2-SADA dose escalation to optimize the safe tumor-targeting protein component (GD2-SADA) dose and dosing interval between GD2-SADA and ¹⁷⁷Lu-DOTA administrations.

- B. ^{177}Lu -DOTA dose escalation to establish optimal, safe payload administration for therapy.
- C. Repeated dosing for assessment of cumulative toxicity signals and safety profile following repeated dosing and determination of the recommended phase 2 dose.

- 5 The patient population will consist of adult and adolescent patients with recurrent or refractory metastatic solid tumors known to express GD2, including Small Cell Lung Cancer (SCLC), Sarcoma and Malignant Melanoma.

The aim of the trial is to establish a safe dosing schedule.

The trial design of part A can be seen in Fig. 3 and table 13 below.

- 10 Table 13. Part A treatment schedule:

	Imaging Part			Therapy Part		
	GD2-SADA dose	Interval (h)	^{177}Lu -DOTA dose	GD2-SADA dose	Interval (h)	^{177}Lu -DOTA dose
Cohort 1	0.3 mg/kg	120	1.1 GBq/ 30 mCi	0.3 mg/kg	120	7.4 GBq/ 30 mCi
Cohort 2	0.3 mg/kg	48	1.1 GBq/ 30 mCi	0.3 mg/kg	48	7.4 GBq/ 30 mCi
Cohort 3	1 mg/kg	48 or 120	1.1 GBq/ 30 mCi	1 mg/kg	48 or 120	7.4 GBq/ 30 mCi
Cohort 4	3 mg/kg	48 or 120	1.1 GBq/ 30 mCi	3 mg/kg	48 or 120	7.4 GBq/ 30 mCi
Cohort 5	10 mg/kg	48 or 120	1.1 GBq/ 30 mCi	10 mg/kg	48 or 120	7.4 GBq/ 30 mCi

Cohort 1: Patients will be administered an intravenous infusion of GD2-SADA on Day 1 followed by an intravenous infusion of ^{177}Lu -DOTA imaging dose on Day 6. On Day 15 a repeated dose of GD2-SADA will be administered followed by a therapy dose of ^{177}Lu -DOTA on day 20.

Cohort 2: Patients will be administered an intravenous infusion of GD2-SADA on Day 1 followed by an intravenous infusion of ^{177}Lu -DOTA imaging dose on Day 3. On Day 15 a repeated dose of GD2-SADA will be administered followed by a therapy dose of ^{177}Lu -DOTA on day 17.

Cohort 3-5: Patients will be dosed on the same days as either Cohort 1 or Cohort 2, depending on the dosing interval between GD2-SADA and ^{177}Lu -DOTA selected after analysis of data from the first two cohorts.

- 5 In Part A dosimetry including tumor absorbed dose and whole body, selected organ absorbed doses and blood dosimetry will be assessed.

Part A will consist of a 6-week DLT observation period and a follow-up period lasting up to 24 weeks after first treatment.

- 10 Assuming a 48-hour interval between GD2-SADA and ^{177}Lu -DOTA is selected in Part A, patients will be administered an intravenous infusion of GD2-SADA on Day 1 followed by an intravenous infusion of ^{177}Lu -DOTA on day 3. On day 15, a repeated dose of GD2-SADA will be administered followed by a therapy dose of ^{177}Lu -DOTA on day 17.

- 15 On Day 43 (GD2-SADA) and Day 45 (^{177}Lu -DOTA) the second treatment cycle will be administered.

The trial design of Part B can be seen in table 14 below.

Table 14: Part B Treatment schedule

	Imaging Part			Therapy Part		
	GD2-SADA dose (Day 1)	Interval (h)	^{177}Lu -DOTA dose (Day 3)	GD2-SADA dose (Day 15 & 43)	Interval (h)	^{177}Lu -DOTA dose (Day 17 and 45)
Cohort 1	Dose selected in Part A	48	1.1 GBq/ 30 mCi	Dose selected in Part A	48	14.8 GBq/ 400 mCi
Cohort 2	Dose selected in Part A	48	1.1 GBq/ 30 mCi	Dose selected in Part A	48	22.2 GBq/ 600 mCi
Cohort 3	Dose selected in Part A	48	1.1 GBq/ 30 mCi	Dose selected in Part A	48	27.8 GBq/ 750 mCi

- 20 Part B will consist of a 6-week DLT observation period and a follow-up period lasting up to 24 weeks after first treatment.

The treatment scheduled in Part C assumes a 48-hour interval between GD2-SADA and ^{177}Lu -DOTA has been selected in Part A. Patients will be administered an intravenous infusion of GD2-SADA on Day 1 followed by an intravenous infusion of ^{177}Lu -DOTA imaging dose on Day 3.

On Day 15, a repeated dose of GD2-SADA will be administered followed by a therapy dose of ^{177}Lu -DOTA on Day 17.

First treatment cycle (Imaging Part followed by Therapy Part) is planned to have a duration of 6 weeks, and subsequent cycles (cycle 2-5) are planned to be 4 weeks (or when recovery from radiation toxicities incurred – a maximum delay of 8 weeks was permitted within this protocol) with GD2-SADA dosing on Day 1 and ^{177}Lu -DOTA dosing on Day 3 of each cycle. See Table 15 for Treatment schedule.

Table 15. Part C treatment Schedule:

	Imaging Part			Treatment cycle 1-5		
	GD2-SADA dose (Day 1)	Interval (h)	^{177}Lu-DOTA dose (Day 3)	GD2-SADA dose (Day 15 of cycle 1 and Day 1 of cycle 2-5)	Interval (h)	^{177}Lu-DOTA dose (Day 17 of cycle 1 and Day 3 of cycle 2-5)
All patients	Dose selected in Part A	48	1.1 GBq/ 30 mCi	Dose selected in Part A	48	Dose selected in Part B

Part C will consist of a 6-week treatment cycle (Cycle 1) followed by up to 4 treatment cycles (Cycles 2-5) with a duration of 4 weeks each and a follow-up period lasting up to 52 weeks after first treatment.

Pre-medication including analgesic is mandatory and introduced based on experience from anti-GD2 IgG-based monoclonal antibodies. Administration scheme can be seen below in Table 16.

Table 16. GD2-SADA Pre- and post-medication

Day	Medication
-1	Analgesic: Gabapentin 300 mg x1
0	Analgesic: Gabapentin 300 mg x2
1 (0,5-1 h prior to SADA infusion)	Analgesic: Morphine sulfate (50 mcg/kg) IV 30 min prior to initiation of GD2 SADA infusion
	Anti-inflammatory: dexamethasone 10 mg IV (or equivalent)
	Anti-nausea: Ondansetron (Zofran), 8 mg PO or equivalent.
	Antipyretic: Acetaminophen (paracetamol) 1 g PO (or equivalent),
2	Analgesic: Gabapentin 300 mg x3
	Anti-inflammatory: dexamethasone 10 mg PO (or equivalent)
3	Analgesic: Gabapentin 300 mg x3

Sequences:

SEQ ID NO. 1: KASQSVSNDVT

5 SEQ ID NO. 2: SASNRYS

SEQ ID NO. 3: QQDYSS

SEQ ID NO. 4: NYGVH

SEQ ID NO. 5: VIWAGGITNYNSAFMS

SEQ ID NO. 6: RGGHYGYALDY

10 SEQ ID NO. 7:

EIVMTQTPATLSVSAGERVTITCKASQSVSNDVTWYQQKPGQAPRLLIYSASNRYS GVPARFSGSGYGTE
 FTFTISSVQSEDFAVYFCQQDYSSFGCGTKLEIKRGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGQQVQ
 LVESGPGVVPGRSLRISCAVSGFSVTNYGVHWVRQPPGKCLEWLGVIWAGGITNYNSAFMSRLTISKD
 NSKNTVYLQMNSLRAEDTAMYYCASRGGHYGYALDYWGQGTTLTVSS

15 SEQ ID NO. 8:

EIVMTQTPATLSVSAGERVTITCKASQSVSNDVTWYQQKPGQAPRLLIYSASNRYS GVPARFSGSGYGTE
 FTFTISSVQSEDFAVYFCQQDYSSFGCGTKLEIKR

SEQ ID NO. 9:

QVQLVESGPGVVQPGRSLRISCAVSGFSVTNYGVHWVRQPPGKCLEWLGVIWAGGITNYNSAFMSRLTI
SKDNSKNTVYLQMNSLRAEDTAMYYCASRGGHYGYALDYWGQGTTLTVSS

SEQ ID NO. 10:

5 QAVVTQEPLTVSPGGTVTLTCGSSTGAVTASNYANWVQQKPGQCPRGLIGGHNNRPPGVPARFSGSL
LGGKAALTLLGAQPEDEAEYYCALWYSDHWVIGGGTKLTVLG

SEQ ID NO. 11:

HVQLVESGGGLVQPGGSLRLSCAASGFSLT DYGVHWVRQAPGKGLEWLGVIWSGGGTAYNTALISRFTI
SRDNSKNTLYLQMNSLRAEDTAVYYCARRGSYPYNYFDAWGCGLTVTVSS

10 SEQ ID NO. 12: KPLDGEYFTLQIRGRERFEMFRELNEALELKDAQAGKEP

SEQ ID NO. 13: RSPDDELLYLPVRGRETYEMLLKIKESLELMQYLPQHTIETYRQQQQQQHQHLLQK

SEQ ID NO. 14: RHGDEDTYYLQVRGRENFEILMKLKESELELMELVPQPLVDSYRQQQQLLQRP

SEQ ID NO. 15: QAIKKELTQIKQKVDSLLENLEKIEKE

SEQ ID NO. 16: STRRILGLAIESQDAGIKTITMLDEQKEQLNRIEEGLDQINKDMRETEKLTTEL

15 SEQ ID NO. 17:

MCGAPSATQPATAETQHIADQVRSQLEEKENKKFPVFKAVSFKSQVVAGTNYFIKVHVGDEDFVHLRVF
QSLPHENKPLTLSNYQTNKAKHDELTYP

SEQ ID NO. 18: DEISMMGRVVVKVEKQVQSIHKLDLLLGFY

SEQ ID NO. 19:

20 TVAEAKRQAAEDALAVINQQEDSSESCWNCGRKASETCSGCNTARYCGSFCQHKDWEKHH

SEQ ID NO. 20: GGGGS

SEQ ID NO. 21: TPLGDTTHT

SEQ ID NO. 22:

EIVMTQTPATLSVSAGERVTITCKASQSVSNDVTWYQQKPGQAPRLIYSASNRYSGVPARFSGSGYGTE
25 FTFTISSVQSEDFAVYFCQQDYSSFGCGTKLEIKRGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGVQ
LVESGPGVVQPGRSLRISCAVSGFSVTNYGVHWVRQPPGKCLEWLGVIWAGGITNYNSAFMSRLTISKD
NSKNTVYLQMNSLRAEDTAMYYCASRGGHYGYALDYWGQGTTLTVSSGGGGSGGGGSGGGGSGGGG
GSHVQLVESGGGLVQPGGSLRLSCAASGFSLT DYGVHWVRQAPGKGLEWLGVIWSGGGTAYNTALISR
FTISRDNSKNTLYLQMNSLRAEDTAVYYCARRGSYPYNYFDAWGCGLTVTVSSGGGGSGGGGSGGGGSGGGG
30 GGGGSGGGGSGGGGSGAVVTQEPLTVSPGGTVTLTCGSSTGAVTASNYANWVQQKPGQCPRGLIGG
HNNRPPGVPARFSGSLLGGKAALTLLGAQPEDEAEYYCALWYSDHWVIGGGTKLTVLGTPLGDTTHTSG
KPLDGEYFTLQIRGRERFEMFRELNEALELKDAQAGKEPGGSGGA

SEQ ID NO. 23: TGAVTASNY

SEQ ID NO. 24: GHN

SEQ ID NO. 25: ALWYSDHWV

SEQ ID NO. 26: GFSLTDYG

SEQ ID NO. 27: IWSGGGT

5 SEQ ID NO. 28: ARRGSPYNYFDA

SEQ ID NO. 29: EDIYNR

SEQ ID NO. 30: GAT

SEQ ID NO. 31: QQYWSNPYT

SEQ ID NO. 32: GFSLTSYG

10 SEQ ID NO. 33: MWRGGST

SEQ ID NO. 34: AKSMITTGFVMD

SEQ ID NO. 35:

QVQLQESGPGLVKPSSETLSLTCTVSGFSLTSYGVHWVRQPPGKGLEWIGVMWRGGSTDYNAAFKSRVTI
SKDNSKNQVSLKLSSVTAADTAVYYCAKSMITTGFVMDSWGQGTTLTVSSGGGGSGGGGSGGGGSGG
15 GGS GGGSGGGGSDIQLTQSPSSLSASVGDRVTITCKASEDIYNRLTWYQQKPGKAPKLLISGATSLETGV
PSRFSGSGSGKDYFTFTISLQPEDFATYYCQQYWSNPYTFGQGTKLEIK

SEQ ID NO. 36:

DIQLTQSPSSLSASVGDRVTITCKASEDIYNRLTWYQQKPGKAPKLLISGATSLETGVPSRFSGSGSGKDYTF
TISSLQPEDFATYYCQQYWSNPYTFGQGTKLEIK

20 SEQ ID NO. 37:

QVQLQESGPGLVKPSSETLSLTCTVSGFSLTSYGVHWVRQPPGKGLEWIGVMWRGGSTDYNAAFKSRVTI
SKDNSKNQVSLKLSSVTAADTAVYYCAKSMITTGFVMDSWGQGTTLTVSS

SEQ ID NO. 38:

QVQLQESGPGLVKPSSETLSLTCTVSGFSLTSYGVHWVRQPPGKGLEWIGVMWRGGSTDYNAAFKSRVTI
25 SKDNSKNQVSLKLSSVTAADTAVYYCAKSMITTGFVMDSWGQGTTLTVSSGGGGSGGGGSGGGGSGG
GGSGGGSGGGGSDIQLTQSPSSLSASVGDRVTITCKASEDIYNRLTWYQQKPGKAPKLLISGATSLETGV
PSRFSGSGSGKDYFTFTISLQPEDFATYYCQQYWSNPYTFGQGTKLEIKGGGGSGGGGSGGGGSGGGG
HVQLVESGGGLVQPGGSLRLSCAASGFSLTDYGVHWVRQAPGKGLEWLGVIWSGGGTAYNTALISRTI
SRDNSKNTLYLQMNSLRAEDTAVYYCARRGSPYNYFDAWGQGTTLTVSSGGGGSGGGGSGGGGSGG
30 GGS GGGSGGGGSAVVTQEPSLTVSPGGTVTLTCSSTGAVTASNANWVQQKPGQAPRGLIGGHN
NRPPGVPARFSGSLLGGKAALTLLGAQPEDEAEYYCALWYSDHWVIGGGTKLTVLGTPLGDTTHTSGKPL
DGEYFTLQIRGRERFEMFRELEALELKDAQAGKEPGSGGAP

SEQ ID NO. 39:

35 QVQLVQSGAEVKKPGASVKVSCKASGYFTFTNYDINWVRQATGQGLEWMGWIFPGDGSTQYNEKFQG

RVTMTTNTSISTAYMELSSLRSED TAVYYCARQTTATWFAYWGQGLTVTVSSGGGGSGGGGSGGGGSG
GGGSGGGGSGGGGSEIVMTQSPATLSVTPKEKVTITCRASQSISDYLHWYQQKPDQSPKLLIKYASQSISG
VPSRFSGSGSGSDFTLTINSLEAEDAATYYCQNGHSFPLTFGQGTKLEIKGGGGSGGGGSGGGGSGGGGSG
5 HVQLVESGGGLVQPGGSLRLSCAASGFSLT DYGVHWVRQAPGKGLEWLGVIWSGGGTAYNTALISRFTI
SRDNSKNTLYLQMNSLRAEDTAVYYCARRGSPYNYFDAWGQGLTVTVSSGGGGSGGGGSGGGGSGGG
GGSGGGGSGGGGSGQAVVTQEPSLTVSPGGTVTLTCGSSTGAVTASNANWVQQKPGQAPRGLIGGHN
NRPPGVPARFSGSLLGGKAALTLLGAQPEDEAEYYCALWYSDHWVIGGGTKLTVLGTPLGDTTHTSGKPL
DGEYFTLQIRGRERFEMFRELNEALELKDAQAGKEPGGSGGAP

10 SEQ ID NO: 40:

QIVLSQSPAILSASPGEKVTMTCRASSSVSYIHWFQQKPGSSPKPWYATSNLASGVPVRFSGSGSGTSYSL
TISRVEAEDAATYYCQQWTSNPPTFGGGTKLEIKGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGQV
QLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPGRGLEWIGAIYPGNGDTSYNQKFKGKAT
LTADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGDWYFNVWGAGTTVTVSAGGGGSGGGGSGGGGSG
15 GGGGSHVQLVESGGGLVQPGGSLRLSCAASGFSLT DYGVHWVRQAPGKGLEWLGVIWSGGGTAYNTA
LISRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARRGSPYNYFDAWGQGLTVTVSSGGGGSGGGGSGGG
GGSGGGGSGGGGSGGGGSGQAVVTQEPSLTVSPGGTVTLTCGSSTGAVTASNANWVQQKPGQAPRG
LIGGHNNRPPGVPARFSGSLLGGKAALTLLGAQPEDEAEYYCALWYSDHWVIGGGTKLTVLGTPLGDTT
HTSGKPLDGEYFTLQIRGRERFEMFRELNEALELKDAQAGKEPGGSGGA

20 SEQ ID NO: 41:

EVQLVESGGGLVKPGGSLRLSCAASGFAFSTYDMSWVRQAPGKCLEWVSTISSGGSYTYADSVKGRFTI
SRDNAKNSLYLQMNSLRAEDTAVYYCAPTTVPFAYWGQGLTVTVSAGGGGSGGGGSGGGGSGGGGSG
GGGGSGGGGSDIQMTQSPSSLSASVGDRVTITCKASQNVRTTVVAWYQQKPGKAPKTLIYLASNRHTGV
PSRFSGSGSGTEFTLTISNLQPEDFATYYCLQHWSYPLTFGCGTKLEVKRGGGGSGGGGSGGGGSGGGG
25 SHVQLVESGGGLVQPGGSLRLSCAASGFSLT DYGVHWVRQAPGKGLEWLGVIWSGGGTAYNTALISRFT
ISRDNSKNTLYLQMNSLRAEDTAVYYCARRGSPYNYFDAWGCGTLTVTVSSGGGGSGGGGSGGGGSGGG
GGSGGGGSGGGGSGQAVVTQEPSLTVSPGGTVTLTCGSSTGAVTASNANWVQQKPGQCPRGLIGGHN
NRPPGVPARFSGSLLGGKAALTLLGAQPEDEAEYYCALWYSDHWVIGGGTKLTVLGTPLGDTTHTSGKPL
DGEYFTLQIRGRERFEMFRELNEALELKDAQAGKEPGGSGGAP

30

Claims

1. An aqueous composition comprising

- 5 a. A SADA-complex, comprising a SADA domain, a first binding site, a second binding site, in an amount of 5-50 g/L;
- b. A buffer-system;
- c. One or more stabilizing agent(s); and
- d. One or more surfactant(s).

10 2. The composition of claim 1, where in the pH is in the range of 5-6.

 3. The composition according to claim 1 or 2, wherein the ionic strength is in the range of 5-150 mM.

15 4. The composition according to any of the preceding claims, wherein the ionic strength is in a range selected among 5-150mM, 15-135mM, 20-120mM and 25-100mM.

20 5. The composition according to any of the preceding claims, comprising a SADA-complex in an amount selected among 5-50 g/L, 6.25-45 g/L, 7.5-40 g/L, 9.75-35 g/L, 10-30 g/L, 11.25-25 g/L, 12.5-20 g/L, 13.75-17.5 g/L and preferably 15 g/L.

 6. The composition according to any of the preceding claims, wherein the first binding site is capable of binding to a tumor antigen.

25 7. The composition according to claim 6, wherein the first binding site is capable of binding to GD2, B7-H3, CD20, GPA33 or CD38.

8. The composition according to claim 7, wherein the first binding site is capable of binding GD2, comprises the CDR sequences shown in SEQ ID NO: 1-6, and has at least 90%, 95%, 96%, 97%, 98% or preferably at least 99% sequence identity to SEQ ID NO: 7.

5

9. The composition according to claim 7, wherein the first binding site is capable of binding GD2, and comprises:

a. a polypeptide comprising a sequence with at least 90%, 95%, 96%, 97%, 98% or preferably at least 99% sequence identity to SEQ ID NO: 8, and

10

b. a polypeptide comprising a sequence with at least 90%, 95%, 96%, 97%, 98% or preferably at least 99% sequence identity to SEQ ID NO: 9.

10. The composition according to claim 7, wherein the first binding site is capable of binding to CD38, comprises the CDR sequences shown in SEQ ID NO: 29-34 and has at least 90%, 95%, 96%, 97%, 98% or preferably at least 99% sequence identity to SEQ ID NO: 35.

15

11. The composition according to claim 7, wherein the first binding site is capable of binding CD38 and comprises:

20

a. a polypeptide comprising a sequence with at least 90%, 95%, 96%, 97%, 98% or preferably at least 99% sequence identity to SEQ ID NO: 36, and

b. a polypeptide comprising a sequence with at least 90%, 95%, 96%, 97%, 98% or preferably at least 99% sequence identity to SEQ ID NO: 37.

25

12. The composition according to any of the claims 6 - 11, wherein the second binding site is capable of binding to a chelator, or a chelator complexing a metal ion.

13. The composition according to claim 12, wherein the second binding site is capable of binding to DOTA, Benzyl-DOTA, a compound comprising the DOTA ring system; or is capable of binding DOTA complexing a metal ion, e.g. lutetium.
- 5 14. The composition according to claim 13, wherein the second binding site comprises a polypeptide with a sequence comprising the CDR sequences of SEQ ID NO: 23-28.
15. The composition according to claim 14, wherein the second binding site comprises:
- 10 a. a polypeptide comprising a sequence with at least 90 %, 95%, 96%, 97% 98% or preferably at least 99% sequence identity, to SEQ ID NO: 10, and
- b. a polypeptide comprising a sequence with at least 90 %, 95%, 96%, 97% 98% or preferably at least 99% sequence identity, to SEQ ID NO: 11.
- 15 16. The composition according to any of the preceding claims, wherein the SADA-domain comprises a polypeptide with a sequence according to SEQ ID NO: 12-19, or a sequence that differs from one of SEQ ID NO: 12-19 by 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 substitutions.
- 20 17. The composition according to claim 16, where the SADA-domain comprises a polypeptide with the sequence of amino acids 6-36 of SEQ ID NO: 12.
18. The composition according to any of the preceding claims, wherein the SADA complex further comprises one or more linkers.
- 25 19. The composition according to claim 18, wherein the SADA complex comprises one or more linkers with a sequence selected among SEQ ID NO 20 multiplied by an integer between 1-6 and SEQ ID NO: 21.

20. The composition according to any of the preceding claims wherein the SADA complex comprises a sequence according to SEQ ID NO 22, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40 or SEQ ID NO: 41.

5 21. The composition according to any of the preceding claims, wherein the buffer system comprises an organic acid or an alkali metal salt thereof.

22. The composition according to claim 21, wherein the organic acid is selected among: acetate, citrate, histidine, citrate-histidine, acetate-histidine and succinate.

10

23. The composition according to claim 21 or 22, wherein the buffer comprises Sodium Acetate.

15

24. The composition according to any of the preceding claims, comprising a buffer in an amount selected among 5-100 mM, 15-50 mM and preferably 20 mM.

25. The composition according to any of the preceding claims, wherein the one or more stabilizing agent(s) is/are selected among polyols, sugar alcohols and non-reducing sugars.

20

26. The composition according to claim 25, wherein the stabilizing agent is sucrose.

25

27. The composition according to any of the preceding claims comprising a stabilizing agent in an amount selected among 200-350 mM, 250-300 mM, and preferably 275 mM.

28. The composition according to any of the preceding claims, wherein the one or more surfactant(s) is/are selected among nonionic surfactants such as Polyethylene glycol

sorbitan monolaurate, Poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol) or Polyethylene glycol sorbitan monooleate .

29. The composition according to claim 28, wherein the surfactant is Polyethylene glycol sorbitan monolaurate.

30. The composition according to any of the preceding claims comprising a surfactant in an amount selected among 0.1-0.3 g/L, 0.15-0.25 g/l, and preferably 0.20 g/L.

31. The composition according to any of the preceding claims, wherein the pH is selected among 5-6, 5.2-5.8, 5.4-5.6 and preferably 5.5.

32. The composition according to any of the previous claims, further comprising an antioxidant.

33. The composition according to claim 32, wherein the antioxidant is Methionine.

34. The composition according to claim 32 or 33, comprising an antioxidant in an amount selected among 5-15 mM, 8-12 mM and preferably 10 mM.

35. The composition according to any of the preceding claims, wherein the composition does not comprise NaCl or comprises NaCl in a low concentration.

36. The composition of claim 35, where the concentration of NaCl is below 50 mM.

37. The composition according to any of the preceding claims, comprising

- a. a SADA-complex comprising or consisting of the amino acid sequence of SEQ ID NO: 22, in an amount of about 15 g/L;
- b. Sodium acetate in an amount of about 20 mM;
- c. Sucrose in an amount of about 275 mM;
- 5 d. Polysorbate 20 in an amount of about 0.2 g/L; and
- e. 10 mM methionine;

wherein the pH is 5.5.

38. The composition according to any of the preceding claims, wherein the composition
10 is a pharmaceutical composition.

39. Use of a composition according to any of the previous claims for treating or
diagnosing cancer.

15 40. Use according to claim 40, for treating or diagnosing a cancer expressing GD2, B7-H3, CD20, GPA33 or CD38.

41. Use according to claim 39 or 40, wherein said cancer is selected among
neuroblastoma, melanoma, sarcoma, brain tumor or carcinoma.

20 42. Use according to any of the claims 39 - 41, wherein said cancer is selected among osteosarcoma, liposarcoma, fibrosarcoma, malignant fibrous histiocytoma, leiomyosarcoma, spindle cell sarcoma, brain tumor, small cell lung cancer, retinoblastoma, HTLV-1 infected T cell leukemia and other GD2 or CD38 positive
25 tumors.

43. Use according to any of the claims 39 - 42, in a method comprising the steps:
- a. Administering a composition according to any of the claims 1 - 38, to a patient in need of the treatment or diagnosing; and
 - b. After a period administering a DOTA-compound comprising a radionuclide.

5

44. Use according to claim 43, wherein the method further comprises administering a clearing agent after step a. and before step b.

10

45. Use according to claim 43 or 44, wherein the radionuclide is selected among an alpha, beta and positron emitting radionuclide.

46. Use according to claim 45, wherein the radionuclide is selected from the group consisting of ^{177}Lu , $^{99\text{m}}\text{Tc}$, ^{64}Cu , ^{90}Y and ^{89}Zr .

15

47. Kit comprising the composition of the claims 1 - 38, and a DOTA compound.

48. Kit according to claim 47, further comprising a radionuclide.





Fig. 1




Fig. 2

2/5




Fig. 3




Fig 4.




Fig. 5

INTERNATIONAL SEARCH REPORT

International application No

PCT/DK2022/050279

A. CLASSIFICATION OF SUBJECT MATTER INV. A61K39/395 A61K33/00 C07K14/47 ADD.		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) A61K C07K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) EPO-Internal		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2018/204873 A1 (MEMORIAL SLOAN KETTERING CANCER CENTER [US]) 8 November 2018 (2018-11-08) claim 2; example 2 -----	1-48
X	CA 3 180 445 A1 (MEMORIAL SLOAN KETTERING CANCER CENTER [US]) 2 December 2021 (2021-12-02) paragraphs [0175], [0176] -----	1-48
X	WO 2020/210232 A1 (MEMORIAL SLOAN KETTERING CANCER CENTER [US]) 15 October 2020 (2020-10-15) paragraph [0333] ----- -/--	1-48
☒ Further documents are listed in the continuation of Box C. ☒ See patent family annex.		
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance;; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance;; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search		Date of mailing of the international search report
1 March 2023		07/03/2023
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016		Authorized officer Patti, Gabriele

INTERNATIONAL SEARCH REPORT

International application No

PCT/DK2022/050279

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	VIOLA MARGARIDA ET AL: "Subcutaneous delivery of monoclonal antibodies: How do we get there?", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 286, 2 August 2018 (2018-08-02), pages 301-314, XP085478006, ISSN: 0168-3659, DOI: 10.1016/J.JCONREL.2018.08.001 paragraph [0004] -----	1-48
X	NEAL WHITAKER ET AL: JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 106, no. 11, 1 November 2017 (2017-11-01), pages 3230-3241, XP055449627, US ISSN: 0022-3549, DOI: 10.1016/j.xphs.2017.06.017 page 3230, column 2nd -----	1-48
X	UCHIYAMA SUSUMU ED - SHUGAR DAVID ET AL: "Liquid formulation for antibody drugs", BIOCHIMICA ET BIOPHYSICA ACTA (BBA) - PROTEINS & PROTEOMICS, ELSEVIER, NETHERLANDS, vol. 1844, no. 11, 13 August 2014 (2014-08-13), pages 2041-2052, XP029050319, ISSN: 1570-9639, DOI: 10.1016/J.BBAPAP.2014.07.016 Introduction -----	1-48
X	J Kang ET AL: "Rapid Formulation Development for Monoclonal Antibodies - BioProcess InternationalBioProcess International", / 12 April 2016 (2016-04-12), XP055349129, Retrieved from the Internet: URL:http://www.bioprocessintl.com/manufacturing/formulation/rapid-formulation-development-for-monoclonal-antibodies/ [retrieved on 2017-02-23] the whole document table 1 -----	1-48
X,P	WO 2022/167052 A1 (Y MABS THERAPEUTICS INC [US]; J MOELLER SAN PEDRO CLAUS [DK]) 11 August 2022 (2022-08-11) page 7, line 21 - line 26; claims 1, 26 -----	1-48

INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK2022/050279

Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item 1.c of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing:
 - a. ☒ forming part of the international application as filed.
 - b. ☐ furnished subsequent to the international filing date for the purposes of international search (Rule 13*ter*.1(a)).

☐ accompanied by a statement to the effect that the sequence listing does not go beyond the disclosure in the international application as filed.
2. ☐ With regard to any nucleotide and/or amino acid sequence disclosed in the international application, this report has been established to the extent that a meaningful search could be carried out without a WIPO Standard ST.26 compliant sequence listing.
3. Additional comments:

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/DK2022/050279

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2018204873 A1	08-11-2018	AU 2018261891 A1 CA 3062439 A1 EP 3652537 A1 US 2020155698 A1 WO 2018204873 A1	21-11-2019 08-11-2018 20-05-2020 21-05-2020 08-11-2018
CA 3180445 A1	02-12-2021	AU 2021280272 A1 CA 3180445 A1 WO 2021242848 A1	19-01-2023 02-12-2021 02-12-2021
WO 2020210232 A1	15-10-2020	AU 2020270888 A1 CA 3136251 A1 CN 114341176 A EP 3953385 A1 IL 287039 A JP 2022525435 A KR 20220006065 A US 2022177579 A1 WO 2020210232 A1	04-11-2021 15-10-2020 12-04-2022 16-02-2022 01-12-2021 13-05-2022 14-01-2022 09-06-2022 15-10-2020
WO 2022167052 A1	11-08-2022	NONE	